Tim Eisen

1.4k total citations
29 papers, 901 citations indexed

About

Tim Eisen is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Tim Eisen has authored 29 papers receiving a total of 901 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 15 papers in Molecular Biology and 12 papers in Cancer Research. Recurrent topics in Tim Eisen's work include Renal cell carcinoma treatment (20 papers), Renal and related cancers (13 papers) and Cancer Genomics and Diagnostics (12 papers). Tim Eisen is often cited by papers focused on Renal cell carcinoma treatment (20 papers), Renal and related cancers (13 papers) and Cancer Genomics and Diagnostics (12 papers). Tim Eisen collaborates with scholars based in United Kingdom, Italy and United States. Tim Eisen's co-authors include Bernard Escudier, Peter F.A. Mulders, Lucy Gossage, Cora N. Sternberg, Ferrán Algaba, Vesa Kataja, J.-J. Patard, Camillo Porta, Vincent Khoo and Caroline Robert and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Clinical Cancer Research.

In The Last Decade

Tim Eisen

27 papers receiving 894 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tim Eisen United Kingdom	14	617	529	329	301	78	29	901
Jakub Żołnierek Poland	11	788 1.3×	617 1.2×	452 1.4×	442 1.5×	98 1.3×	23	1.1k
David F. McDermott United States	8	572 0.9×	510 1.0×	294 0.9×	441 1.5×	109 1.4×	12	915
Olga Valota Italy	14	563 0.9×	436 0.8×	258 0.8×	346 1.1×	118 1.5×	43	891
Hao‐Wen Sim Australia	17	327 0.5×	364 0.7×	299 0.9×	326 1.1×	95 1.2×	73	931
Yongfeng Yu China	17	395 0.6×	368 0.7×	197 0.6×	411 1.4×	76 1.0×	64	844
L Pyle United Kingdom	12	359 0.6×	441 0.8×	235 0.7×	301 1.0×	65 0.8×	18	810
Dmitry Nosov Russia	12	941 1.5×	533 1.0×	410 1.2×	542 1.8×	201 2.6×	40	1.2k
К. К. Лактионов Russia	17	633 1.0×	335 0.6×	285 0.9×	779 2.6×	45 0.6×	100	1.2k
Alexandr Poprach Czechia	21	632 1.0×	981 1.9×	848 2.6×	433 1.4×	107 1.4×	107	1.6k
Huamao Mark Lin United States	18	618 1.0×	317 0.6×	166 0.5×	582 1.9×	42 0.5×	73	1.0k

Countries citing papers authored by Tim Eisen

Since Specialization

Citations

This map shows the geographic impact of Tim Eisen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Eisen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Eisen more than expected).

Fields of papers citing papers by Tim Eisen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Eisen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Eisen. The network helps show where Tim Eisen may publish in the future.

Co-authorship network of co-authors of Tim Eisen

This figure shows the co-authorship network connecting the top 25 collaborators of Tim Eisen. A scholar is included among the top collaborators of Tim Eisen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim Eisen. Tim Eisen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Oza, Bhavna, Eleni Frangou, Tim Eisen, et al.. (2025). Determining the Impact of Histology on the Incidence, Pattern, and Timing of Recurrences in Patients with Renal Cell Carcinoma: A Pooled Analysis from the SORCE and ASSURE Trials. European Urology Open Science. 79. 19–26.

Frangou, Eleni, Grant D. Stewart, Ian D. Davis, et al.. (2025). LBA93 First results from RAMPART: An international phase III randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL. Annals of Oncology. 36. S1635–S1635.

Ince, Will & Tim Eisen. (2021). Combination therapies in clinical trials for renal cell carcinoma: how could they impact future treatments?. Expert Opinion on Investigational Drugs. 30(12). 1221–1229. 5 indexed citations

Klatte, Tobias, Kevin Gallagher, Luca Afferi, et al.. (2019). The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort. BMC Medicine. 17(1). 182–182. 21 indexed citations

Eisen, Tim, Eleni Frangou, Ben Smith, et al.. (2019). Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An international, randomised double-blind phase III trial led by the MRC CTU at UCL. Annals of Oncology. 30. v891–v892. 14 indexed citations

Molina, Ana M., Thomas E. Hutson, Dmitry Nosov, et al.. (2018). Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study. European Journal of Cancer. 94. 87–94. 34 indexed citations

Sun, Maxine, Lorenzo Marconi, Tim Eisen, et al.. (2018). Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. European Urology. 74(5). 611–620. 62 indexed citations

Eisen, Tim, Yaroslav Shparyk, Nicholas MacLeod, et al.. (2015). A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results. British Journal of Cancer. 113(8). 1140–1147. 32 indexed citations

Blinman, Prunella, Ian D. Davis, Andrew Martin, et al.. (2015). Patients' preferences for adjuvant sorafenib after resection of intermediate or high-risk renal cell carcinoma in the SORCE trial: What makes it worthwhile?. Journal of Clinical Oncology. 33(7_suppl). 415–415. 1 indexed citations

10.

Eisen, Tim, Gunnar Hedlund, G. Forsberg, & Robert D. Hawkins. (2014). Naptumomab Estafenatox: Targeted Immunotherapy with a Novel Immunotoxin. Current Oncology Reports. 16(2). 370–370. 15 indexed citations

11.

Sternberg, Cora N., Tim Eisen, Piotr Tomczak, et al.. (2013). Tivozanib in patients treatment-naive for metastatic renal cell carcinoma: A subset analysis of the phase III TIVO-1 study.. Journal of Clinical Oncology. 31(15_suppl). 4513–4513. 8 indexed citations

12.

Escudier, Bernard, Tim Eisen, Camillo Porta, et al.. (2012). Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 23. vii65–vii71. 231 indexed citations

13.

Eisen, Tim, Cora N. Sternberg, Caroline Robert, et al.. (2012). Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies. JNCI Journal of the National Cancer Institute. 104(2). 93–113. 156 indexed citations

14.

Motzer, Robert J., Tim Eisen, Oleg Lipatov, et al.. (2012). O4 Tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from the Phase III randomized, open-label, multicenter TIVO-1 trial. European Urology Supplements. 11(5). 185–185. 15 indexed citations

15.

Rini, Brian I., Tim Eisen, Wolfram Brugger, et al.. (2011). IMA901 Multipeptide Vaccine Randomized International Phase III Trial (IMPRINT): A randomized, controlled study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC.. Journal of Clinical Oncology. 29(15_suppl). TPS183–TPS183. 11 indexed citations

16.

Seidl, Thomas, James Larkin, Claudia Wellbrock, et al.. (2010). The melanocortin receptor agonist NDP‐MSH impairs the allostimulatory function of dendritic cells. Immunology. 129(4). 610–619. 9 indexed citations

17.

Escudier, B., David Cella, C. Sternberg, et al.. (2010). A randomized double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment-naive locally advanced or metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 28(15_suppl). TPS237–TPS237. 4 indexed citations

18.

Nathan, Paul, John Wagstaff, Emilio Porfiri, Tom Powles, & Tim Eisen. (2009). UK guidelines for the systemic treatment of renal cell carcinoma. British Journal of Hospital Medicine. 70(5). 284–286. 6 indexed citations

19.

Bukowski, Ronald M., D.Y.C. Heng, Tim Eisen, et al.. (2008). SORAFENIB IN ADVANCED RENAL CELL CARCINOMA (RCC): SURVIVAL AND BIOMARKER RESULTS FROM A PHASE III TRIAL. European Urology Supplements. 7(3). 245–245. 4 indexed citations

20.

Vaughan, Matthew, J. Moore, SR Johnston, et al.. (2000). GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): A phase I trial in melanoma. Annals of Oncology. 11(9). 1183–1190. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact